



Noninvasive cardiac imaging by CT & MR


Change of Diagnostic Workflow



Clinical Examples

Which Questions may be answered
Advantages for Patient / Referral
Place in Diagnostic Algorithm

CT in the Clinical Diagnostic of Cardiac Disease




R. Rienmüller (1983) Thesis

EBT 2001

„CTCA is a valuable clinical tool, that has the potential to improve the investigation of cardiac patients.

CTCA will undoubtedly become both more prevalent and more useful as access and technology improves.“





Spatial resolution 1.5 mm
Time resolution < 50 ms



Spatial resolution $< 0.7 \text{ mm}$
Time resolution $\cong 165 \text{ ms}$

Dual Source CT




Spatial resolution $< 0.7 \text{ mm}$
Time resolution $\cong 83 \text{ ms}$

CT– Technologien

Modalität	Scanzeit	Bemerkungen
Single Slice	ca 1000 ms	Schichtdicke ca 1mm
Spiral	ca 500-700 ms	
Multislice, Multidetector (16, 32, 64 - 256)	ca 330-500 ms (165 ms)	Isotrope Bild Voxel
Dual Source	165 ms (84 ms)	Isotrope Bild Voxel
EBT (UFCT) (1. Multislice & Multidetector System)	50-100 ms	Schichtdicke 1,5 mm

Benötigt wird eine Scanzeit von ca 20 ms, ca 10 Mal während einer Herzaktion für die Dauer von ca 40 Herzaktionen als Volumenscan



Spatial resolution $< 0.5 \text{ mm}$
Time resolution $< 30 \text{ ms}$

34 y male with Known Coarctation of the Aorta

Present History: disorder of sleep with dyspnoe and episodes of choking, peripheral edema, acute cardiac decompensation


Risk factors: Hypertension (RR:r 150/60 mm Hg, RR:l 135/60 mm HG), Bicuspid valve, Aortic insufficiency, Nicotin,

Medication: Seloken ret. plus, Lasix 20 mg

Diagnostic evaluation: Catheterisation, CTA, MR



34 y male with Coarctation of the Aorta

MSCT 64



34 y male with Coarctation of the Aorta

MSCT 64







34 y male with Coarctation of the Aorta

MSCT 64



W.S., ♂, 37 YO



34 y male with Known Coarctation of the Aorta

Findings


MSCT 64: Bicuspid valve, Dilatation of ascending aorta and of the anomalous supraaortic vessels, Severe (afew mm) stenosis, Bypassing circulation by dilated internal thoracic arteries, by dilated intercostal arteries (III), by dilated lateral thoracic arteries, by dilated rete scapulare

Normal origin of LCA and RCA, thin LAD, CX and RCA


EBT: (Borderline) myocardial perfusion of 63 ml/100g/min at HR of 78 min⁻¹, RR 180/80 mm HG

34 y male with Coarctation of the Aorta

Cardiac MR



140 cm/s



Work in Progress. *G. Reiter, U. Reiter, R. Rienmüller*

34 y male with Known Coarctation of the Aorta

MR:	EDV – 232 ml,	ESV – 138 ml,	SV – 93 ml,
	EF – 40,3%,	LVMM – 176 g	
Asc. Aorta:	Forward-Flow		80 ml
	Reverse-Flow		35 ml
	Net Forward-Flow		45 ml
	Poststenotic Desc. Aorta		0,078 ml
	r. Intercostal artery		5 ml
	l. Intercostal artery		8 ml
	Desc. Aorta prox.		15 ml
	Desc. Aorta dist.		14 ml

Suggested

therapy: short term: interventional treatment of the stenosis
long term: aortic valve and ascending aorta surgery

Coronary Heart Disease

„... is the Manifestation of **Atherosclerosis** in the Coronary Arteries. As the Disease is a Multifactorial Process Leading to **Myocardial Ischemia**, it may Appear as Angina Pectoris, Myocardial Infarction, Cardiac Dysrhythmia, Sudden Death or Cardiac Insufficiency. The Course of the Disease may be **Silent**.“

Clinical Question

- 1) Does the patient have **coronary atherosclerosis**?
(Stage, Localization, Kind of sclerosis, Degree of stenosis)
- 2) Does the patient have **myocardial ischemia**?
- 3) How big is the individual **myocardial perfusion**
(ml/100g/min)?
- 4) Which **mechanism** may prevent or reduce myocardial ischemia?
- 5) Does the patient have **myocardial infarction**?
- 6) Which parts of the myocardium are **viable**?
- 7) How big is the individual **coronary reserve**?

74 y anxious female with CAD and Hypertension

Present History:

Angina at night for two years

Past History:

3 y ago: suspected MI and stroke,
Non-conclusive CA

Medication: TASS 100 mg, Plavix,
Nomexor, Iterium, Dancor, Temesta,
Plendil ret., Tebonin ret.

Hospitalisation: July 6-11, 2005

Coronary Angiography rejected

Ergo- and Tl-Scint. not done

CT-Angiography recommended

Blood pressure allways in „lower normal range“



Traditional approach in patients with suspected CHD

Patients history
Physical findings
Chest X-ray
ECG
Echocardiography
Cardiac Scintigraphy
Labor parameters
Coronary angiography

Praesentation Herz Bypass XC00050136
Cor SSK 1.0 MIP 65%
UniKlinRadGraz
Sensation Cardiac 64
25-Jan-2005 11:45:31
CT

RES/SHADE/SURF



B 100 W 547
O 52 C 219



Traditional approach in patients with suspected CHD

Chest X-ray

ECG

Echo

SPECT

Labor parameters

Indirect methods, **No visualization** of coronary arteries and **No measuring** of myocardial perfusion in (ml/100g/min)

Coronary angiography

≈ Luminography **No visualization** of coronary walls and myocardial perfusion

No relationship between extend of luminal stenosis and myocardial perfusion


„Angiographic Evidence of The Severity of Coronary Stenosis is **not** Correlated with Physiological and Clinical Effects.

„There is **no** Apparent Relation between the Severity of Coronary Lesions and their Propensity to Cause Future Cardiac Events. Most Lesions Resulting in Cardiac Events are **not** Severely Stenotic.“

As cited by *G. Levine et al.* N Engl J Med, 1995; 332:512-521

74 y anxious female with CAD and Hypertension

EDV	100	[105 ± 10] ml
ESV	29	[30 ± 5] ml
EF	71	[>70] %
CO	3,6	[5 ± 0.5] l/min
LVMM	70	g
HR	54	min ⁻¹
RR	120/75	mm Hg
Ca ⁺⁺ Score	67	[0]



Myocardial Perfusion global = **54** [75 ± 10] ml/100g/min
ant.wall = **49** [75 ± 10] ml/100g/min

Perf/HR = **1.00** [1 ± 0.3]

Perf/RPP = **0.0083** [0.009]

LAD > **90 %** → **3,5 cm**

> **50 %** → **5-7 cm**

Diagonal > **50 %** → **0,5 cm**

74 y anxious female with CAD and Hypertension

Procedure after CTA:

- Referring physician informed by phone + letter
- Patient referred to EBA (Emergency)
- Patient came to Radiology
- Patient referred to Dep. of Cardiology
- ECG – Stress test negative
- Patient send home
- Patient continues to complain
- Cardiology LKH-West
- Coronary angiography – CTA-Diagnosis confirmed and by Drug eluting Stents dilatation performed, and antihypertensive therapy adapted to present Hypotension

W.S., m 63y


Symptoms: Chest pain

Findings: LAD – hard & soft plaques,
Stenosis > 50%
RCA – hypoplastic

Ca Score: 110

Perfusion: globally reduced
to 41ml/100g/min
at HR of 52 /min,
RR of 119/76 mmHg

**Morphology
& Function:** EDV – 162 ml,
LVMM – 169, EF – 65%



Calcium Scoring

“Increased Calcium Score adds to the risk profile and can trigger preventive treatment”

De Bacher G, et all: Eur Heart J. 24 (17): 1601-10; 2003

“The routine assessment of the Coronary Calcium Score is still under debate”

Hamilton MCK, et all: BMJ 2003; 326: 1045-1046

Clinical Question

- What is the smallest **soft** and **calcified** plaque to be identified by CT?
- How does Ca^{++} score correlate
 - with **soft** plaque?
 - with **stenotic** lesions?
 - with **age**?

Coronary calcium and plaque burden




20%
Calcified

80%
Fibrotic
Lipid Rich


Plaque
Detectable
by IVUS,
Pathology

Courtesy of R. Vliegenthart PhD
Lecture at ESCR Meeting Berlin 2004

Logistic Regression Analysis in Patients with Suspected Coronary Heart Disease



Calcium Score vs Age



f and m
 n = 1541
 r = 0,2039
 p = 0,0001

score
 mean = 529
 sd = 1031
 min = 0
 max = 7854

age
 mean = 61
 sd = 13
 min = 16
 max = 88

female
 n = 549
 r = 0,164
 p = 0,0001

score
 mean = 393
 sd = 840
 min = 0
 max = 7310

age
 mean = 63
 sd = 13
 min = 18
 max = 88


male
 n = 991
 r = 0,25
 p = 0,0001

score
 mean = 604
 sd = 1116
 min = 0
 max = 7853

age
 mean = 59
 sd = 12
 min = 16
 max = 85

95% ci for r = 0,1555 to 0,2513 (f and m)
 95% ci for r = 0,0822 to 0,2451 (female)
 95% ci for r = 0,1939 to 0,3105 (male)

Co-factors of Ca⁺⁺ Score



	Age	lvmm	Syst.	RPP	CO	SV	HR	Perfusion	Aortic Compliance
n	1472	1410	1462	1459	1308	1311	1474	1412	805
r	0.25	0.15	0.08	0,04	0,02	0	-0,01	-0,02	-0,13
r ²	0.14	0.03	0.02	0	0	0	0	0	0.04
p	0	0	0	0.12	0.02	0.94	0.6	0.44	0

M.S., m 73y

Symptoms: post Stent, occlusion?



Findings: LAD – hard & soft plaques,
with stenosis > 50% before
open stent,
R.intermedius – multipl.stenosis > 50%

Ca Score: 673

Perfusion: globally reduced – 47 ml/100g/min
at HR of 49 /min,
RR of 164/95 mmHg

**Morphology
& Function:** EDV – 120 ml, LVMM – 98 g,
EF – 66%





CT – Coronary Angiography (CTCA)

CTCA tends to overestimate coronary stenosis compared to invasive coronary angiography
pos. pred. value – ca.80%
neg. pred. value – ca.95%

Achenbach et al. Eur J Radiol 2006

CT Bypass Sensitivity for occlusion up to 100%
Sensitivity and specificity for stenosis
ca. 95/ 89% (Cave Metal clip)

Pache et al. EHJ 2006

CT Stent Specificity and sensitivity ca. 98/ 83%
(Cave geometry \emptyset should be above 2 mm, right reconstruction Kernel)

Cademartiri et al. AJC 2005

Diagnostic Accuracy of EBT / MSCT vs. Angiography for Stenotic Lesions > 50%

n = 222 patients,
2220 segments,
disease prevalence 45%

n = 20 patients,
200 segments,
disease prevalence 10%

All segments

All segments

Sensitivity (%)

67

73

Specificity (%)

74

96

PPV (%)

23

73


NPV (%)

92

96




Cine SA True-Fisp




Late Enhancement: Flash 2D


Intima Sarcoma




T1






T2



T2FS





Late Enhancement




Cine TrueFISP

TI



ASD



Aortenklappenersatz



Change of Diagnostic Workflow by Cardiac CT and MR

[IC]²
Berlin

Clinical Examples

Which Questions may be answered

Advantages for Patient / Referral

Place in Diagnostic Algorithm

Indication for Cardiac CT/MR- studies?

CT

- 1) „Subclinical“ CHD
- 2) Chronic Coronary Syndrom
- 3) Coronary stenosis > 50%
- 4) Myocardial infarction
- 5) Myocardial ischemia
- 6) Pericardial diseases
- 7) Anomaly of coronary vessels
- 8) Bypass-stenosis/-occlusion
- 9) Stent-occlusion

MR

- Infarction/ „Vitality“
- Myocardial scare
- Myocarditis
- Valve vitium
- Pericardial Constriction
- Cardial Thrombus/ Tumor
- ARVD
- Shunt



Change of Diagnostic Workflow by Cardiac CT and MR

[IC]²
Berlin

Clinical Examples

Which Questions may be answered

Advantages for Patient / Referral

Place in Diagnostic Algorithm

Benefit for the Patient

Objective, non invasive, reproducible, fast method for exclusion or for early recognition and staging of coronary, cardiac and pulmonary diseases as **One Stop Shop.**

Benefit for the Referrals

Objective, non invasive, quantitative, reproducible, fast method for exclusion or for early recognition and staging of coronary, cardiac and pulmonary diseases as **One Stop Shop**.

Therapy recommendation and control of its individual effectiveness (**evidence based medicine**).

Benefit for Cardiologists

Reduction of unnecessary coronary catheterization.

Increase capacity for interventional procedures.

Objective, non invasive, quantitative, reproducible, fast method for exclusion or for early recognition and staging of coronary, cardiac and pulmonary diseases as **One Stop Shop**.

Therapy selection and control of its individual effectiveness (**evidence based medicine**).



Change of Diagnostic Workflow by Cardiac CT and MR




Clinical Examples

Which Questions may be answered

Advantages for Patient / Referral

Place in Diagnostic Algorithm

Risk Profile of CHD



CT enables noninvasive direct visualization of soft- and calcified coronary arterial plaques – “The potential of this information for risk stratification has sparked intense interest in plaque imaging to identify patients at high risk of a coronary event”

S. Achenbach 2007

New Concept for Evaluation of patients with suspected or known CHD

1. Step: Visualization of micro-pathology and patho-physiology by

MSCT, (DSCT, EBT) and MR

2. Step: Evaluation of etiology and accompanying individual health issues as history, physical findings, **HR** and **RR**, laboratory parameters, ECG – Arrhythmia (Sympath./Parasympath.), Echo – Valvular disease

(Cyclotron-PET) – Metabolism, Perfusion (ml/100g/min)

Conclusion I:

Non-Invasive In Vivo Visualisation Of Organ Micro-Pathology and Patho-Physiology

Will create new diagnostic work-up → **new work-flow**:

- **“First look Doctor”** in whole body **One-Stop-Shop** with Computed assisted diagnostic devices (pattern recognition) with therapeutical options
- **Target history** taking and **target physical examination** with additional tests dependent on individual patient's situation

Conclusion II:

Non-Invasive In Vivo Visualisation Of Organ Micro-Pathology and Patho-Physiology

Will demand for:

- New **match** of the (imaging) diagnostician and (therapeutic) clinicians
- Reform of medical **education** (radio-patho-anatomy and radio-patho-physiology)
- Implication of “**autopsy**” by CT/MR technologies with target biopsy and adequate evaluation.

Conclusion III:

Non-Invasive In Vivo Visualization Of Organ Micro-Pathology and Patho-Physiology

Will result in:

Effective, science-based, transparent, economic, individual
patient orientated

new Health-Care System

open for genetic and molecular biology implementation



Change of Diagnostic Workflow by Cardiac CT and MR

[IC]²
Berlin

Thank you for your attention!

R.Rienmüller

B.Schröttner

H.Mächler

J.Teubl

U.Reiter

W.Klein

P.Lyszcz

M.Kutateladze

N.Gagarina

K.Kovaleva

M.Zink

O.Waltersdorfer

R. Reiter